<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03982069</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY19040242</org_study_id>
    <secondary_id>1U01|P001035-01</secondary_id>
    <nct_id>NCT03982069</nct_id>
  </id_info>
  <brief_title>Immunologic Response to FluMist vs. Flucelvax</brief_title>
  <official_title>Immunological Response to Influenza Vaccination in Children, Adolescents, and Young Adults: A RCT of FluMist vs. Flucelvax</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Richard Zimmerman MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate immunologic response to different types of influenza&#xD;
      vaccine among children/adolescents/young adults 4-21 years of age. This is a randomized&#xD;
      controlled trial (RCT), that will assess immune response in about 440 participants (about 220&#xD;
      per vaccine arm) pre- and post-vaccination to FluMist (live attenuated influenza vaccine&#xD;
      given by nasal administration) and Flucelvax (egg-free cell-culture inactivated influenza&#xD;
      vaccine).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-blinded, randomized controlled trial analyzing influenza vaccine immunogenicity&#xD;
      response in children/adolescents/young adults aged 4-21 years given one of two FDA approved&#xD;
      and licensed influenza vaccines: FluMist (live attenuated influenza vaccine by nasal&#xD;
      administration) and Flucelvax (egg-free cell-culture inactivated influenza vaccine). This&#xD;
      study will enroll about 440 healthy participants, about 220 per vaccine arm. Participants&#xD;
      will be randomized in blocks of 4 using a 1:1 allocation to receive either FluMist or&#xD;
      Flucelvax. Blood work will be conducted on all participants at baseline prior to vaccine&#xD;
      receipt and post-vaccination at Day 7 (range 6-9 days) and Day 28 (range 21-35 days). The&#xD;
      primary objective of the study is to determine pre- and post-serologic responses to each&#xD;
      vaccine type.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 20, 2019</start_date>
  <completion_date type="Actual">December 9, 2020</completion_date>
  <primary_completion_date type="Actual">December 9, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Seroconversion Response In 2019</measure>
    <time_frame>Post-vaccination (at Day 28 timepoint)</time_frame>
    <description>Rows in data tables represent different influenza antigens measured in 2019. Hemagglutination inhibition (HI) assay was conducted to assess immunologic outcome. Seroconversion is defined as a 4-fold or higher rise in HI titer post-vaccination given a pre-vaccination HI titer of &gt;=10 and a final HI titer of &gt;=40.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Seroconversion Response In 2020</measure>
    <time_frame>Post-vaccination (at Day 28 timepoint)</time_frame>
    <description>Rows in data tables represent different influenza antigens measured in 2020. Hemagglutination inhibition (HI) assay was conducted to assess immunologic outcome. Seroconversion is defined as a 4-fold or higher rise in HI titer post-vaccination given a pre-vaccination HI titer of &gt;=10 and a final HI titer of &gt;=40.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Seroprotection Response in 2019</measure>
    <time_frame>Pre-vaccination (at Day 0 timepoint) and post-vaccination (at Day 28 timepoint)</time_frame>
    <description>Rows in data tables represent different influenza antigens measured in 2019. Hemagglutination inhibition (HI) assay was conducted to assess immunologic outcome. Seroprotection is defined as a HI titer &gt;= 1:110 at either time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) at Each Time Point 2019</measure>
    <time_frame>Pre-vaccination (at Day 0 timepoint) and post-vaccination (at Day 28 timepoint)</time_frame>
    <description>Rows in data tables represent different influenza antigens measured in 2019. Hemagglutination inhibition assay was conducted to assess immunologic outcome. GMTs is defined as the anti-log of the mean of the log2 HI titers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Seroprotection Response in 2020</measure>
    <time_frame>Pre-vaccination (at Day 0 timepoint) and post-vaccination (at Day 28 timepoint)</time_frame>
    <description>Rows in data tables represent different influenza antigens measured in 2020. Hemagglutination inhibition (HI) assay was conducted to assess immunologic outcome. Seroprotection is defined as a HI titer &gt;= 1:110 at either time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) at Each Time Point 2020</measure>
    <time_frame>Pre-vaccination (at Day 0 timepoint) and post-vaccination (at Day 28 timepoint)</time_frame>
    <description>Rows in data tables represent different influenza antigens measured in 2020. Hemagglutination inhibition assay will be conducted to assess immunologic outcome. GMTs is defined as the anti-log of the mean of the log2 HI titers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">465</enrollment>
  <condition>Influenza, Human</condition>
  <condition>Immune Response</condition>
  <arm_group>
    <arm_group_label>FluMist live attenuated influenza vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receiving live attenuated FluMist influenza vaccine will receive 0.2 mL given intranasally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flucelvax inactivated influenza vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receiving inactivated Flucelvax influenza vaccine will receive 0.5 mL given intramuscularly</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FluMist live attenuated influenza vaccine</intervention_name>
    <description>Participants randomized to this study influenza vaccine arm will receive FluMist live attenuated influenza vaccine at baseline after the baseline blood draw is complete.</description>
    <arm_group_label>FluMist live attenuated influenza vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Flucelvax inactivated influenza vaccine</intervention_name>
    <description>Participants randomized to this study influenza vaccine arm will receive Flucelvax cell-culture inactivated influenza vaccine at baseline after the baseline blood draw is complete.</description>
    <arm_group_label>Flucelvax inactivated influenza vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  aged 4-21 years;&#xD;
&#xD;
          -  has prior vaccination history available (which can be determined based either on&#xD;
             medical record review or through state registry review);&#xD;
&#xD;
          -  plans to receive the current seasonal influenza vaccination at one of the recruiting&#xD;
             sites&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unable or unwilling to completed required study activities, including informed&#xD;
             consent, randomization to vaccine, and bloodwork;&#xD;
&#xD;
          -  has already received influenza vaccine for the current season;&#xD;
&#xD;
          -  has a known immunocompromising condition or is on an immunosuppressing medication&#xD;
             (e.g., high dose steroids &gt;10 days);&#xD;
&#xD;
          -  is known to be pregnant;&#xD;
&#xD;
          -  has a history of severe allergy to eggs or to influenza vaccine or any of its&#xD;
             components&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard K Zimmerman, MD, MPH, MA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh, School of Medicine, Dept. Family Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Academic Pediatrics</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Department of Family Medicine</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 6, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2019</study_first_posted>
  <results_first_submitted>August 18, 2021</results_first_submitted>
  <results_first_submitted_qc>September 17, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 14, 2021</results_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Richard Zimmerman MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in the primary article, after deidentification, will be placed at the site mentioned below.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months after article publication.</ipd_time_frame>
    <ipd_access_criteria>Researchers who provide a methodologically sound proposal and have appropriate data security and privacy plans in place</ipd_access_criteria>
    <ipd_url>http://github.com/pittvax</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 3, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT03982069/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>FluMist Live Attenuated Influenza Vaccine 2019</title>
          <description>Participants receiving live attenuated FluMist influenza vaccine will receive 0.2 mL given intranasally&#xD;
FluMist live attenuated influenza vaccine: Participants randomized to this study influenza vaccine arm will receive FluMist live attenuated influenza vaccine at baseline after the baseline blood draw is complete.</description>
        </group>
        <group group_id="P2">
          <title>Flucelvax Inactivated Influenza Vaccine 2019</title>
          <description>Participants receiving inactivated Flucelvax influenza vaccine will receive 0.5 mL given intramuscularly&#xD;
Flucelvax inactivated influenza vaccine: Participants randomized to this study influenza vaccine arm will receive Flucelvax cell-culture inactivated influenza vaccine at baseline after the baseline blood draw is complete.</description>
        </group>
        <group group_id="P3">
          <title>FluMist Live Attenuated Influenza Vaccine 2020</title>
          <description>Participants receiving live attenuated FluMist influenza vaccine will receive 0.2 mL given intranasally&#xD;
FluMist live attenuated influenza vaccine: Participants randomized to this study influenza vaccine arm will receive FluMist live attenuated influenza vaccine at baseline after the baseline blood draw is complete.</description>
        </group>
        <group group_id="P4">
          <title>Flucelvax Inactivated Influenza Vaccine 2020</title>
          <description>Participants receiving inactivated Flucelvax influenza vaccine will receive 0.5 mL given intramuscularly&#xD;
Flucelvax inactivated influenza vaccine: Participants randomized to this study influenza vaccine arm will receive Flucelvax cell-culture inactivated influenza vaccine at baseline after the baseline blood draw is complete.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="110"/>
                <participants group_id="P3" count="127"/>
                <participants group_id="P4" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="118"/>
                <participants group_id="P4" count="112"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Specimen loss</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FluMist Live Attenuated Influenza Vaccine 2019</title>
          <description>Participants receiving live attenuated FluMist influenza vaccine will receive 0.2 mL given intranasally&#xD;
FluMist live attenuated influenza vaccine: Participants randomized to this study influenza vaccine arm will receive FluMist live attenuated influenza vaccine at baseline after the baseline blood draw is complete.</description>
        </group>
        <group group_id="B2">
          <title>Flucelvax Inactivated Influenza Vaccine 2019</title>
          <description>Participants receiving inactivated Flucelvax influenza vaccine will receive 0.5 mL given intramuscularly&#xD;
Flucelvax inactivated influenza vaccine: Participants randomized to this study influenza vaccine arm will receive Flucelvax cell-culture inactivated influenza vaccine at baseline after the baseline blood draw is complete.</description>
        </group>
        <group group_id="B3">
          <title>FluMist Live Attenuated Influenza Vaccine 2020</title>
          <description>Participants receiving live attenuated FluMist influenza vaccine will receive 0.2 mL given intranasally&#xD;
FluMist live attenuated influenza vaccine: Participants randomized to this study influenza vaccine arm will receive FluMist live attenuated influenza vaccine at baseline after the baseline blood draw is complete.</description>
        </group>
        <group group_id="B4">
          <title>Flucelvax Inactivated Influenza Vaccine 2020</title>
          <description>Participants receiving inactivated Flucelvax influenza vaccine will receive 0.5 mL given intramuscularly&#xD;
Flucelvax inactivated influenza vaccine: Participants randomized to this study influenza vaccine arm will receive Flucelvax cell-culture inactivated influenza vaccine at baseline after the baseline blood draw is complete.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="108"/>
            <count group_id="B2" value="110"/>
            <count group_id="B3" value="127"/>
            <count group_id="B4" value="120"/>
            <count group_id="B5" value="465"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="74"/>
                    <measurement group_id="B5" value="253"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="46"/>
                    <measurement group_id="B5" value="212"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.8" spread="4.6"/>
                    <measurement group_id="B2" value="16.6" spread="4.2"/>
                    <measurement group_id="B3" value="15.6" spread="5.0"/>
                    <measurement group_id="B4" value="15.1" spread="5.2"/>
                    <measurement group_id="B5" value="16.0" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="59"/>
                    <measurement group_id="B5" value="254"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="61"/>
                    <measurement group_id="B5" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="116"/>
                    <measurement group_id="B5" value="439"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="138"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="84"/>
                    <measurement group_id="B5" value="259"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="127"/>
                    <measurement group_id="B4" value="120"/>
                    <measurement group_id="B5" value="465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Seroconversion Response In 2019</title>
        <description>Rows in data tables represent different influenza antigens measured in 2019. Hemagglutination inhibition (HI) assay was conducted to assess immunologic outcome. Seroconversion is defined as a 4-fold or higher rise in HI titer post-vaccination given a pre-vaccination HI titer of &gt;=10 and a final HI titer of &gt;=40.</description>
        <time_frame>Post-vaccination (at Day 28 timepoint)</time_frame>
        <population>2019 Participants</population>
        <group_list>
          <group group_id="O1">
            <title>FluMist Live Attenuated Influenza Vaccine 2019</title>
            <description>Participants receiving live attenuated FluMist influenza vaccine will receive 0.2 mL given intranasally&#xD;
FluMist live attenuated influenza vaccine: Participants randomized to this study influenza vaccine arm will receive FluMist live attenuated influenza vaccine at baseline after the baseline blood draw is complete.</description>
          </group>
          <group group_id="O2">
            <title>Flucelvax Inactivated Influenza Vaccine 2019</title>
            <description>Participants receiving inactivated Flucelvax influenza vaccine will receive 0.5 mL given intramuscularly&#xD;
Flucelvax inactivated influenza vaccine: Participants randomized to this study influenza vaccine arm will receive Flucelvax cell-culture inactivated influenza vaccine at baseline after the baseline blood draw is complete.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Seroconversion Response In 2019</title>
          <description>Rows in data tables represent different influenza antigens measured in 2019. Hemagglutination inhibition (HI) assay was conducted to assess immunologic outcome. Seroconversion is defined as a 4-fold or higher rise in HI titer post-vaccination given a pre-vaccination HI titer of &gt;=10 and a final HI titer of &gt;=40.</description>
          <population>2019 Participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1-A/Brisbane</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2-A/Kansas egg grown virus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2-A/Kansas cell grown virus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria-B/Colorado</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata-B/Phuket</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>All listed antigens</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Seroconversion Response In 2020</title>
        <description>Rows in data tables represent different influenza antigens measured in 2020. Hemagglutination inhibition (HI) assay was conducted to assess immunologic outcome. Seroconversion is defined as a 4-fold or higher rise in HI titer post-vaccination given a pre-vaccination HI titer of &gt;=10 and a final HI titer of &gt;=40.</description>
        <time_frame>Post-vaccination (at Day 28 timepoint)</time_frame>
        <population>2020 Participants</population>
        <group_list>
          <group group_id="O1">
            <title>FluMist Live Attenuated Influenza Vaccine 2020</title>
            <description>Participants receiving live attenuated FluMist influenza vaccine will receive 0.2 mL given intranasally&#xD;
FluMist live attenuated influenza vaccine: Participants randomized to this study influenza vaccine arm will receive FluMist live attenuated influenza vaccine at baseline after the baseline blood draw is complete.</description>
          </group>
          <group group_id="O2">
            <title>Flucelvax Inactivated Influenza Vaccine 2020</title>
            <description>Participants receiving inactivated Flucelvax influenza vaccine will receive 0.5 mL given intramuscularly&#xD;
Flucelvax inactivated influenza vaccine: Participants randomized to this study influenza vaccine arm will receive Flucelvax cell-culture inactivated influenza vaccine at baseline after the baseline blood draw is complete.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Seroconversion Response In 2020</title>
          <description>Rows in data tables represent different influenza antigens measured in 2020. Hemagglutination inhibition (HI) assay was conducted to assess immunologic outcome. Seroconversion is defined as a 4-fold or higher rise in HI titer post-vaccination given a pre-vaccination HI titer of &gt;=10 and a final HI titer of &gt;=40.</description>
          <population>2020 Participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1-A/Hawaii66 egg based antigen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1-A/Hawaii70 cell based antigen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1-A/Delaware</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2-A/Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria-B/Washington</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata-B/Phuket</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>All listed antigens</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Seroprotection Response in 2019</title>
        <description>Rows in data tables represent different influenza antigens measured in 2019. Hemagglutination inhibition (HI) assay was conducted to assess immunologic outcome. Seroprotection is defined as a HI titer &gt;= 1:110 at either time point.</description>
        <time_frame>Pre-vaccination (at Day 0 timepoint) and post-vaccination (at Day 28 timepoint)</time_frame>
        <population>2019 Participants</population>
        <group_list>
          <group group_id="O1">
            <title>FluMist Live Attenuated Influenza Vaccine 2019</title>
            <description>Participants receiving live attenuated FluMist influenza vaccine will receive 0.2 mL given intranasally&#xD;
FluMist live attenuated influenza vaccine: Participants randomized to this study influenza vaccine arm will receive FluMist live attenuated influenza vaccine at baseline after the baseline blood draw is complete.</description>
          </group>
          <group group_id="O2">
            <title>Flucelvax Inactivated Influenza Vaccine 2019</title>
            <description>Participants receiving inactivated Flucelvax influenza vaccine will receive 0.5 mL given intramuscularly&#xD;
Flucelvax inactivated influenza vaccine: Participants randomized to this study influenza vaccine arm will receive Flucelvax cell-culture inactivated influenza vaccine at baseline after the baseline blood draw is complete.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Seroprotection Response in 2019</title>
          <description>Rows in data tables represent different influenza antigens measured in 2019. Hemagglutination inhibition (HI) assay was conducted to assess immunologic outcome. Seroprotection is defined as a HI titer &gt;= 1:110 at either time point.</description>
          <population>2019 Participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1-A/Birsbane:Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1-A/Birsbane:Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2-AKansas egg grown virus: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2-AKansas egg grown virus: Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2-AKansas cell grown virus: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2-AKansas cell grown virus: Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria-B/Colorado: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria-B/Colorado: Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata-B/Phuket: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata-B/Phuket: Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Day 28 for all listed antigens</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.40</p_value>
            <p_value_desc>Day 0, A/H1N1-A/Brisbane</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.36</p_value>
            <p_value_desc>Day 0 A/H1N1-A/Kansas egg grown virus</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <p_value_desc>Day 0 A/H1N1-A/Kansas cell grown virus</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.91</p_value>
            <p_value_desc>Day 0 B/Victoria-B/Colorado</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.31</p_value>
            <p_value_desc>Day 0 B/Yamagata-B/Phuket</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) at Each Time Point 2019</title>
        <description>Rows in data tables represent different influenza antigens measured in 2019. Hemagglutination inhibition assay was conducted to assess immunologic outcome. GMTs is defined as the anti-log of the mean of the log2 HI titers</description>
        <time_frame>Pre-vaccination (at Day 0 timepoint) and post-vaccination (at Day 28 timepoint)</time_frame>
        <population>2019 Participants</population>
        <group_list>
          <group group_id="O1">
            <title>FluMist Live Attenuated Influenza Vaccine 2019</title>
            <description>Participants receiving live attenuated FluMist influenza vaccine will receive 0.2 mL given intranasally&#xD;
FluMist live attenuated influenza vaccine: Participants randomized to this study influenza vaccine arm will receive FluMist live attenuated influenza vaccine at baseline after the baseline blood draw is complete.</description>
          </group>
          <group group_id="O2">
            <title>Flucelvax Inactivated Influenza Vaccine 2019</title>
            <description>Participants receiving inactivated Flucelvax influenza vaccine will receive 0.5 mL given intramuscularly&#xD;
Flucelvax inactivated influenza vaccine: Participants randomized to this study influenza vaccine arm will receive Flucelvax cell-culture inactivated influenza vaccine at baseline after the baseline blood draw is complete.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) at Each Time Point 2019</title>
          <description>Rows in data tables represent different influenza antigens measured in 2019. Hemagglutination inhibition assay was conducted to assess immunologic outcome. GMTs is defined as the anti-log of the mean of the log2 HI titers</description>
          <population>2019 Participants</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1-A/Brisbane: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="77" upper_limit="116"/>
                    <measurement group_id="O2" value="90" lower_limit="73" upper_limit="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1-A/Brisbane: Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108" lower_limit="89" upper_limit="132"/>
                    <measurement group_id="O2" value="269" lower_limit="228" upper_limit="317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2-A/Kansas egg grown virus: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="64" upper_limit="89"/>
                    <measurement group_id="O2" value="78" lower_limit="66" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2-A/Kansas egg grown virus: Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="83" upper_limit="112"/>
                    <measurement group_id="O2" value="205" lower_limit="178" upper_limit="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2-A/Kansas cell grown virus: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="43" upper_limit="58"/>
                    <measurement group_id="O2" value="46" lower_limit="38" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2-A/Kansas cell grown virus: Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" lower_limit="58" upper_limit="74"/>
                    <measurement group_id="O2" value="136" lower_limit="113" upper_limit="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria-B/Colorado: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="53" upper_limit="81"/>
                    <measurement group_id="O2" value="65" lower_limit="53" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria-B/Colorado: Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="64" upper_limit="94"/>
                    <measurement group_id="O2" value="158" lower_limit="134" upper_limit="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata-B/Phuket: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101" lower_limit="83" upper_limit="122"/>
                    <measurement group_id="O2" value="89" lower_limit="74" upper_limit="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata-B/Phuket: Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107" lower_limit="90" upper_limit="128"/>
                    <measurement group_id="O2" value="215" lower_limit="191" upper_limit="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.79</p_value>
            <p_value_desc>Day 0 A/H1N1-A/Brisbane</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.79</p_value>
            <p_value_desc>Day 0 A/H3N2-A/Kansas egg grown virus</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.56</p_value>
            <p_value_desc>Day 0 A/H3N2-A/Kansas cell grown virus</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.95</p_value>
            <p_value_desc>Day 0 B/Victoria-B/Colorado</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.44</p_value>
            <p_value_desc>Day 0 B/Yamagata-B/Phuket</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Day 28 for all listed variables</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Seroprotection Response in 2020</title>
        <description>Rows in data tables represent different influenza antigens measured in 2020. Hemagglutination inhibition (HI) assay was conducted to assess immunologic outcome. Seroprotection is defined as a HI titer &gt;= 1:110 at either time point.</description>
        <time_frame>Pre-vaccination (at Day 0 timepoint) and post-vaccination (at Day 28 timepoint)</time_frame>
        <population>2020 Participants</population>
        <group_list>
          <group group_id="O1">
            <title>FluMist Live Attenuated Influenza Vaccine 2020</title>
            <description>Participants receiving live attenuated FluMist influenza vaccine will receive 0.2 mL given intranasally&#xD;
FluMist live attenuated influenza vaccine: Participants randomized to this study influenza vaccine arm will receive FluMist live attenuated influenza vaccine at baseline after the baseline blood draw is complete.</description>
          </group>
          <group group_id="O2">
            <title>Flucelvax Inactivated Influenza Vaccine 2020</title>
            <description>Participants receiving inactivated Flucelvax influenza vaccine will receive 0.5 mL given intramuscularly&#xD;
Flucelvax inactivated influenza vaccine: Participants randomized to this study influenza vaccine arm will receive Flucelvax cell-culture inactivated influenza vaccine at baseline after the baseline blood draw is complete.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Seroprotection Response in 2020</title>
          <description>Rows in data tables represent different influenza antigens measured in 2020. Hemagglutination inhibition (HI) assay was conducted to assess immunologic outcome. Seroprotection is defined as a HI titer &gt;= 1:110 at either time point.</description>
          <population>2020 Participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1-A/Hawaii66 egg: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1-A/Hawaii66 egg: Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1-A/Hawaii70 cell grown virus: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1-A/Hawaii70 cell grown virus: Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1-A/Delaware: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1-A/Delaware: Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2-A/Hong Kong: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2-A/Hong Kong: Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria-B/Washington: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria-B/Washington: Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata-B/Phuket: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata-B/Phuket: Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.83</p_value>
            <method>Chi-squared</method>
            <method_desc>Day 0: A/H1N1-A/Hawaii66-egg based antigen</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.79</p_value>
            <method>Chi-squared</method>
            <method_desc>Day 0: A/H1N1-A/Hawaii70-cell based antigen</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>Chi-squared</method>
            <method_desc>Day 0: A/H1N1-A/Delaware</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Chi-squared</method>
            <method_desc>Day 0: A/H3N2-A/Hong Kong</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.98</p_value>
            <method>Chi-squared</method>
            <method_desc>Day 0: B/Victoria-B/Washington</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Chi-squared</method>
            <method_desc>Day 0: B/Yamagata-B/Phuket</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Chi-squared</method>
            <method_desc>Day 28: A/H1N1-A/Hawaii66-egg based antigen, A/H1N1-A/Hawaii70-cell based antigen, A/H1N1-A/Delaware, B/Victoria-B/Washington, B/Yamagata-B/Phuket</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.66</p_value>
            <method>Chi-squared</method>
            <method_desc>A/H3N2-A/Hong Kong</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) at Each Time Point 2020</title>
        <description>Rows in data tables represent different influenza antigens measured in 2020. Hemagglutination inhibition assay will be conducted to assess immunologic outcome. GMTs is defined as the anti-log of the mean of the log2 HI titers</description>
        <time_frame>Pre-vaccination (at Day 0 timepoint) and post-vaccination (at Day 28 timepoint)</time_frame>
        <population>2020 Participants</population>
        <group_list>
          <group group_id="O1">
            <title>FluMist Live Attenuated Influenza Vaccine 2020</title>
            <description>Participants receiving live attenuated FluMist influenza vaccine will receive 0.2 mL given intranasally&#xD;
FluMist live attenuated influenza vaccine: Participants randomized to this study influenza vaccine arm will receive FluMist live attenuated influenza vaccine at baseline after the baseline blood draw is complete.</description>
          </group>
          <group group_id="O2">
            <title>Flucelvax Inactivated Influenza Vaccine 2020</title>
            <description>Participants receiving inactivated Flucelvax influenza vaccine will receive 0.5 mL given intramuscularly&#xD;
Flucelvax inactivated influenza vaccine: Participants randomized to this study influenza vaccine arm will receive Flucelvax cell-culture inactivated influenza vaccine at baseline after the baseline blood draw is complete.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) at Each Time Point 2020</title>
          <description>Rows in data tables represent different influenza antigens measured in 2020. Hemagglutination inhibition assay will be conducted to assess immunologic outcome. GMTs is defined as the anti-log of the mean of the log2 HI titers</description>
          <population>2020 Participants</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1-A/Hawaii66 egg grown virus: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" lower_limit="33" upper_limit="52"/>
                    <measurement group_id="O2" value="34" lower_limit="27" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1-A/Hawaii66 egg grown virus: Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="41" upper_limit="63"/>
                    <measurement group_id="O2" value="171" lower_limit="139" upper_limit="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1-A/Hawaii70 cell grown virus: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="80" upper_limit="118"/>
                    <measurement group_id="O2" value="84" lower_limit="61" upper_limit="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1-A/Hawaii70 cell grown virus: Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121" lower_limit="100" upper_limit="145"/>
                    <measurement group_id="O2" value="380" lower_limit="315" upper_limit="458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1-A/Delaware: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="47" upper_limit="72"/>
                    <measurement group_id="O2" value="46" lower_limit="36" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1-A/Delaware: Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="50" upper_limit="78"/>
                    <measurement group_id="O2" value="120" lower_limit="100" upper_limit="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2-A/Hong Kong: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174" lower_limit="133" upper_limit="226"/>
                    <measurement group_id="O2" value="119" lower_limit="89" upper_limit="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2-A/Hong Kong: Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234" lower_limit="190" upper_limit="288"/>
                    <measurement group_id="O2" value="370" lower_limit="282" upper_limit="484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria-B/Washington: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="75" upper_limit="114"/>
                    <measurement group_id="O2" value="88" lower_limit="70" upper_limit="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria-B/Washington: Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116" lower_limit="95" upper_limit="142"/>
                    <measurement group_id="O2" value="212" lower_limit="175" upper_limit="258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata-B/Phuket: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="83" upper_limit="118"/>
                    <measurement group_id="O2" value="87" lower_limit="71" upper_limit="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata-B/Phuket: Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114" lower_limit="96" upper_limit="135"/>
                    <measurement group_id="O2" value="214" lower_limit="184" upper_limit="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <p_value_desc>Day 0: A/H1N1-A/Hawaii66 egg based antigen</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.25</p_value>
            <p_value_desc>Day 0: A/H1N1-A/Hawaii70 cell based antigen</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.13</p_value>
            <p_value_desc>Day 0: A/H1N1-A/Delaware</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <p_value_desc>Day 0: A/H3N2-A/Hong Kong</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.78</p_value>
            <p_value_desc>Day 0: B/Victoria-B/Washington</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.36</p_value>
            <p_value_desc>Day 0: B/Yamagata-B/Phuket</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Day 28: A/H1N1-A/Hawaii66 egg based antigen, A/H1N1-A/Hawaii70 cell based antigen, A/H1N1-A/Delaware, B/Victoria-B/Washington, B/Yamagata-B/Phuket</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <p_value_desc>Day 28: A/H3N2-A/Hong Kong</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 weeks in relation to baseline</time_frame>
      <group_list>
        <group group_id="E1">
          <title>FluMist Live Attenuated Influenza Vaccine</title>
          <description>Participants receiving live attenuated FluMist influenza vaccine will receive 0.2 mL given intranasally&#xD;
FluMist live attenuated influenza vaccine: Participants randomized to this study influenza vaccine arm will receive FluMist live attenuated influenza vaccine at baseline after the baseline blood draw is complete.</description>
        </group>
        <group group_id="E2">
          <title>Flucelvax Inactivated Influenza Vaccine</title>
          <description>Participants receiving inactivated Flucelvax influenza vaccine will receive 0.5 mL given intramuscularly&#xD;
Flucelvax inactivated influenza vaccine: Participants randomized to this study influenza vaccine arm will receive Flucelvax cell-culture inactivated influenza vaccine at baseline after the baseline blood draw is complete.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Katherine Williams</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-383-1979</phone>
      <email>kvw3@pitt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

